AR is common and its prevalence is increasing.3 It can be perennial (where symptoms are typically chronic) or seasonal (with intermittent symptoms triggered by various pollens or spores).3
Compared to patients with mild disease, patients with moderate-severe AR experience more frequent and longer-lasting symptoms, and are likely to have many allergenic triggers.4
Tree, grass and
House dust mites
Contact us to request a pollen & spore poster for your practice
nasal stuffiness with
Impairment of daily
activities (one or more
of sleep, work, school,
AR can significantly reduce patient quality of life and can affect their school or work attendance.6 Additionally, sleep can be disturbed in 50-80% of sufferers, leading to daytime tiredness, poor concentration and mood disorders.7
Ryaltris® is indicated in adults and adolescents 12 years of age and older for first-line treatment of moderate to severe nasal symptoms associated with AR.1
The active ingredients in Ryaltris® are olopatadine (a potent, selective antihistamine) and mometasone furoate (a topical corticosteroid with local anti-inflammatory properties).1
The Ryaltris® recommended dose for adults and adolescents (12 years and older) is two actuations (sprays) in each nostril twice-daily (morning and evening).1
Please consult the Summary of Product Characteristics for more information.
Glenmark Pharmaceuticals has developed a range of support items to help clinicians manage their patients and to support Healthcare Organisations in their decision making.
When you prescribe Ryaltris®, your patients have access to clear information and support to ensure they take their medication correctly. This information is additional to the Patient Information Leaflet (PIL) that comes in every Ryaltris® pack, and is not intended to replace the PIL.
Patients prescribed Ryaltris® can access a dedicated website with information, advice and guidance to help them manage their treatment and their AR. Click here to view.
You can use this to facilitate training with your patients who have been prescribed Ryaltris®. The film can also be accessed from the patient website. Click the play icon to view.
By clicking this link, you are leaving the Ryaltris® website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.
If you wish to continue, please click ‘Continue’, otherwise click ‘Stay on page.’